OncoMatch/Clinical Trials/NCT06509724
Comparison of Conventional and Hypofractionated IMRT in High-Risk Cervical Cancer Post-Radical Hysterectomy
Is NCT06509724 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies non-drug interventions for uterine cervical neoplasms.
Radical hysterectomy and radiation therapy are standard treatments for cervical cancer. However, there are no reported studies on the frequency of side effects and treatment outcomes when hypofractionated radiation therapy and intensity modulated radiation therapy(IMRT) are used during radiation therapy. Hypofractionated radiation therapy increases the daily dose and reduces the number of treatment sessions, which may increase the risk of side effects, but its safety has been confirmed in some cases of early cervical cancer and endometrial cancer. Additionally, applying IMRT, a technique designed to protect normal tissue, during concurrent chemoradiotherapy has shown positive results in reducing the incidence of acute side effects. Investigators previously demonstrated that combining hypofractionated IMRT with chemotherapy for high-risk postoperative cervical cancer patients resulted in high survival rates and low toxicity in a phase 2 exploratory study. Base on this result, this study aimed to compare the efficacy and safety of conventional fractionated radiation therapy and hypofractionated radiation therapy.
Check if I qualifyExtracted eligibility criteria
Cancer type
Cervical Cancer
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: radical hysterectomy
Patients who have undergone radical hysterectomy and pelvic lymphadenectomy
Cannot have received: radiotherapy to the pelvic area
Patients who have previously received radiotherapy to the pelvic area
Cannot have received: neoadjuvant chemotherapy
Patients who received neoadjuvant chemotherapy before surgery
Lab requirements
Blood counts
granulocyte ≥1.0 x 103/µl, platelets ≥30 x 103/µl, hemoglobin ≥9.5 g/dl
Kidney function
creatinine <2.0 mg/dl
Liver function
bilirubin < 1.5 mg/dl
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify